加齢黄斑変性の世界市場レポート 2024年

加齢黄斑変性市場規模は近年力強く成長しています。2023年の91億7,000万米ドルから2024年には99億米ドルへと、CAGR7.9％で拡大します。これまでの期間に見られた拡大は、高齢化を特徴とする人口動態の変化、環境要因の影響を受けたライフスタイルの進化、遺伝的素因、早期診断につながる意識の高まり、診断技術の進歩に起因しています。

加齢黄斑変性（AMD）市場は、中心視力を司る網膜の重要な部分である黄斑部を侵す進行性の眼疾患であるAMDの有病率の増加によって成長が見込まれます。加齢黄斑変性の治療は疾患の重症度を軽減することを目的としており、AMDの有病率の上昇は市場成長に寄与する重要な要因です。英国のレーザー眼科治療専門企業Optimaxa社の報告によると、2023年2月現在、世界中で約1億9,600万人が加齢黄斑変性（AMD）に罹患しており、2040年には2億8,800万人に増加すると予測されています。これは世界人口の8.7％に相当します。AMDの有病率の増加は、効果的な治療法の必要性を強調し、加齢黄斑変性市場成長の主要な促進要因となっています。

高齢化社会の拡大は、加齢黄斑変性市場の成長に大きく貢献すると予想されます。高齢化社会とは、65歳以上の高齢者の割合の増加や数の増加を特徴とする人口動態の変化を意味します。世界の高齢者人口の増加に伴い、AMDの有病率も増加しています。例えば、カナダを拠点に最新動向に関するビジュアルコンテンツの作成に注力しているVisual Capitalist社によると、2022年には世界の65歳以上の人口は7億7,100万人で、世界人口のほぼ10％を占める。その結果、高齢化人口の拡大が加齢黄斑変性市場の成長を促進する重要な要因となっています。

北米は、2023年の加齢黄斑変性世界市場において最大の地域です。アジア太平洋は予測期間中に最も急成長する地域となる見込みです。加齢黄斑変性市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の加齢黄斑変性市場促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の加齢黄斑変性市場の規模実績と成長率、2018年～2023年
• 世界の加齢黄斑変性市場の規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の加齢黄斑変性市場、タイプ別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 滲出性加齢黄斑変性（AMD）
• 乾燥性加齢黄斑変性（AMD）
• 世界の加齢黄斑変性市場、薬剤別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• アイリーア
• ルセンティス
• アバスチン
• その他の製品
• 世界の加齢黄斑変性市場、投与経路別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 静脈内
• 硝子体内
• 世界の加齢黄斑変性市場、流通チャネル別セグメンテーション、実績および予測、2018年～2023年、2023年～2028年、2033年
• 病院薬局
• 専門薬局
• オンライン薬局

第7章 地域および国の分析

• 世界の加齢黄斑変性市場、地域別、実績および予測、2018年～2023年、2023年～2028年、2033年
• 世界の加齢黄斑変性市場、国別、実績および予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 加齢黄斑変性市場の競合情勢
• 加齢黄斑変性市場企業プロファイル
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Bausch Health Companies Inc.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“Age-Related Macular Degeneration Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on age-related macular degeneration market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for age-related macular degeneration? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The age-related macular degeneration market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type: Wet Age-Related Macular Degeneration (AMD); Dry Age-Related Macular Degeneration (AMD)
• 2) By Drug: Eylea; Lucentis; Avastin; Other Products
• 3) By Route Of Administration: Intravenous; Intravitreal
• 4) By Distribution Channel: Hospital Pharmacy; Specialty Pharmacy; Online Pharmacy
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Bayer AG; Pfizer Inc.; Bausch Health Companies Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Age-related macular degeneration (AMD) is a progressive eye condition characterized by the deterioration of the macula, located at the center of the retina, resulting in a gradual loss of central vision due to aging. Therapeutic options for AMD encompass regular eye examinations, lifestyle modifications, and specific nutritional supplements.

There are two main types of age-related macular degeneration, wet age-related macular degeneration (AMD) and dry age-related macular degeneration (AMD). Wet AMD is a progressive eye disease marked by the growth of abnormal blood vessels beneath the macula, the central part of the retina responsible for sharp, central vision. Treatment for wet AMD involves the use of various drugs such as Eylea, Lucentis, Avastin, and others. These drugs are administered through intravenous and intravitreal routes and are typically dispensed through hospital pharmacies, specialty pharmacies, and online pharmacies.

The age-related macular degeneration market research report is one of a series of new reports from The Business Research Company that provides age-related macular degeneration market statistics, including age-related macular degeneration industry global market size, regional shares, competitors with an age-related macular degeneration market share, detailed age-related macular degeneration market segments, market trends and opportunities, and any further data you may need to thrive in the age-related macular degeneration industry. This age-related macular degeneration market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The age-related macular degeneration market size has grown strongly in recent years. It will grow from $9.17 billion in 2023 to $9.9 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The expansion observed in the historical period can be attributed to demographic shifts characterized by an aging population, evolving lifestyles influenced by environmental factors, genetic predisposition, heightened awareness leading to early diagnosis, and advancements in diagnostic techniques.

The age-related macular degeneration market size is expected to see strong growth in the next few years. It will grow to $13.1 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth in the forecast period can be attributed to ongoing research in genetics and biomarkers, the emergence of novel therapeutic modalities, the increasing prominence of telemedicine and remote monitoring, as well as a focus on patient advocacy and education. Major trends expected in the forecast period include the adoption of personalized medicine approaches, innovations in retinal imaging technologies, the rise of sustained drug delivery systems, an increase in clinical trials for investigational therapies, and collaborative efforts in research and development.

The anticipated growth in the age-related macular degeneration (AMD) market is expected to be driven by the increasing prevalence of AMD, a progressive eye condition that affects the macula, a crucial part of the retina responsible for central vision. Treatments for age-related macular degeneration aim to mitigate the severity of the disease, and the rising prevalence of AMD is a significant factor contributing to market growth. According to reports from Optimaxa, a UK-based laser eye treatment specialist, as of February 2023, approximately 196 million individuals worldwide are affected by age-related macular degeneration (AMD), with projections estimating a rise to 288 million by 2040. This would account for 8.7 percent of the global population. The escalating prevalence of AMD underscores the need for effective treatments and is a key driver for the growth of the age-related macular degeneration market.

The expanding aging population is expected to contribute significantly to the growth of the age-related macular degeneration market. The aging population represents a demographic shift characterized by a higher proportion or an increasing number of individuals aged 65 years and older. As the global elderly population increases, there is a corresponding rise in the prevalence of AMD. For instance, in 2022, according to Visual Capitalist, a Canada-based company focused on creating visual content about the latest trends, there were 771 million people aged 65 years and older globally, accounting for almost 10% of the world's population. Consequently, the expanding aging population is a key factor driving the growth of the age-related macular degeneration market.

Product innovations emerge as a prominent trend in the age-related macular degeneration (AMD) market, with major companies actively developing novel products and drugs to solidify their market position. An example of this trend is evident in the actions of Genentech Inc., a leading US-based biotechnology and pharmaceutical company. In October 2021, Genentech received regulatory approval from the US Food and Drug Administration for its groundbreaking Susvimo (ranibizumab) therapy. This therapy is designed for patients suffering from wet AMD. Susvimo stands out as a sustained-release implant that delivers ranibizumab, preventing the growth of abnormal blood vessels in the retina. Notably, this innovative drug offers a more convenient and less invasive treatment option compared to traditional eye injections, marking a significant advancement in AMD treatment.

Major companies in the age-related macular degeneration market are engaging in strategic partnerships and collaborations to fortify their market presence. Strategic partnerships involve collaborative relationships formed between two or more organizations to achieve specific business objectives or goals. An illustrative case is the collaboration between Mosaic Biosciences, a US-based biotechnology company, and Ocular Therapeutix, a US-based pharmaceutical company. In June 2021, these companies entered into a research collaboration aimed at developing a drug to treat patients with dry age-related macular degeneration. This strategic partnership not only strengthens the companies' research and development portfolios but also presents a high-growth opportunity.

In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. Through this acquisition, Astellas Pharma aims to expand its presence in the ophthalmology market and accelerate the development of novel treatments for age-related macular degeneration. IVERIC Bio Inc., a US-based biotech corporation, specializes in the development of drugs and products for treating age-related macular degeneration, making it a strategic addition to Astellas Pharma's portfolio in the ophthalmology sector.

Major companies operating in the age-related macular degeneration market report are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Amgen Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., AbbVie Inc., Outlook Therapeutics Inc., Biogen Inc., Samsung Bioepis Co. Ltd., Allergan plc, Biocon Ltd., Bio-Thera Biopharmaceutical Co. Ltd., AstraZeneca plc, Acucela Inc., Ophthotech Corporation, Kodiak Sciences Inc., REGENXBIO Inc., Alkahest Inc., Opthea Limited, Apellis Pharmaceuticals Inc., Graybug Vision Inc., IVERIC bio Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., Tyrogenex Inc., Chengdu Kanghong Pharmaceutical Group Co. Ltd., I-Mab Biopharma Co. Ltd., pSivida Corp., Clearside Biomedical Inc., SciFluor Life Sciences LLC, Lineage Cell Therapeutics Inc.

North America was the largest region in the global age-related macular degeneration market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the age-related macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the age-related macular degeneration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The age-related macular degeneration market consists of sales of anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy (PDT), low-vision aids, and telescopic lenses. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Age-Related Macular Degeneration Market Characteristics

3. Age-Related Macular Degeneration Market Trends And Strategies

4. Age-Related Macular Degeneration Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global Age-Related Macular Degeneration Market Size and Growth

• 5.1. Global Age-Related Macular Degeneration Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Age-Related Macular Degeneration Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Age-Related Macular Degeneration Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Age-Related Macular Degeneration Market Segmentation

• 6.1. Global Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Wet Age-Related Macular Degeneration (AMD)
• Dry Age-Related Macular Degeneration (AMD)
• 6.2. Global Age-Related Macular Degeneration Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Eylea
• Lucentis
• Avastin
• Other Products
• 6.3. Global Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Intravenous
• Intravitreal
• 6.4. Global Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy

7. Age-Related Macular Degeneration Market Regional And Country Analysis

• 7.1. Global Age-Related Macular Degeneration Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Age-Related Macular Degeneration Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Age-Related Macular Degeneration Market

• 8.1. Asia-Pacific Age-Related Macular Degeneration Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Age-Related Macular Degeneration Market

• 9.1. China Age-Related Macular Degeneration Market Overview
• 9.2. China Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Age-Related Macular Degeneration Market

• 10.1. India Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Age-Related Macular Degeneration Market

• 11.1. Japan Age-Related Macular Degeneration Market Overview
• 11.2. Japan Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Age-Related Macular Degeneration Market

• 12.1. Australia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Age-Related Macular Degeneration Market

• 13.1. Indonesia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Age-Related Macular Degeneration Market

• 14.1. South Korea Age-Related Macular Degeneration Market Overview
• 14.2. South Korea Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Age-Related Macular Degeneration Market

• 15.1. Western Europe Age-Related Macular Degeneration Market Overview
• 15.2. Western Europe Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Age-Related Macular Degeneration Market

• 16.1. UK Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Age-Related Macular Degeneration Market

• 17.1. Germany Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Age-Related Macular Degeneration Market

• 18.1. France Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Age-Related Macular Degeneration Market

• 19.1. Italy Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Age-Related Macular Degeneration Market

• 20.1. Spain Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Age-Related Macular Degeneration Market

• 21.1. Eastern Europe Age-Related Macular Degeneration Market Overview
• 21.2. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Age-Related Macular Degeneration Market

• 22.1. Russia Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Age-Related Macular Degeneration Market

• 23.1. North America Age-Related Macular Degeneration Market Overview
• 23.2. North America Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Age-Related Macular Degeneration Market

• 24.1. USA Age-Related Macular Degeneration Market Overview
• 24.2. USA Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Age-Related Macular Degeneration Market

• 25.1. Canada Age-Related Macular Degeneration Market Overview
• 25.2. Canada Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Age-Related Macular Degeneration Market

• 26.1. South America Age-Related Macular Degeneration Market Overview
• 26.2. South America Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Age-Related Macular Degeneration Market

• 27.1. Brazil Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Age-Related Macular Degeneration Market

• 28.1. Middle East Age-Related Macular Degeneration Market Overview
• 28.2. Middle East Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Age-Related Macular Degeneration Market

• 29.1. Africa Age-Related Macular Degeneration Market Overview
• 29.2. Africa Age-Related Macular Degeneration Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Age-Related Macular Degeneration Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Age-Related Macular Degeneration Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Age-Related Macular Degeneration Market Competitive Landscape And Company Profiles

• 30.1. Age-Related Macular Degeneration Market Competitive Landscape
• 30.2. Age-Related Macular Degeneration Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche Ltd.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Bayer AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Pfizer Inc.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Bausch Health Companies Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Age-Related Macular Degeneration Market Competitive Benchmarking

32. Global Age-Related Macular Degeneration Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Age-Related Macular Degeneration Market

34. Age-Related Macular Degeneration Market Future Outlook and Potential Analysis

• 34.1 Age-Related Macular Degeneration Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Age-Related Macular Degeneration Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Age-Related Macular Degeneration Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer